Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02564588 · ClinicalTrials.gov registry record · Phase 2
Dasotraline Binge Eating Disorder Study
A Phase 2 study of Binge-Eating Disorder, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 2
- Development phase
- 319
- Enrollment target
- 20
- Study locations
NCT02564588: Completed Phase 2 study of Binge-Eating Disorder, sponsored by Sumitomo Pharma America.
NCT02564588 is a Phase 2 study of Binge-Eating Disorder that has completed, run by Sumitomo Pharma America. The registered enrollment target is 319 participants, below the 1,135-participant average among 37 other Binge-Eating Disorder trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02564588, a Phase 2 study of Binge-Eating Disorder, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 319 participants
- Enrollment target
- 20
- Study locations
Study Summary
Evaluate the efficacy of flexibly-dosed dasotraline compared with placebo in adults with moderate to severe Binge Eating Disorder (BED)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dasotraline
Study Locations (20)
California
- Southern California Research - Beverly Hills
- Southwestern Research, Inc. - Beverly Hills
- Pharmacology Research Institute - Encino
- Collaborative NeuroScience Network Inc. - Garden Grove
- Pharmacology Research Institute - Newport Beach
- PCSD- Feighner Research - San Diego
- Research Across America - Santa Ana
Florida
- Clinical Neuroscience Solutions, Inc. - Jacksonville
- Segal Institute for Clinical Research - North Miami
- Clinical Neuroscience Solutions, Inc. - Orlando
- Miami Research Associates - South Miami
Georgia
- Institute of Advanced Medical Research - Alpharetta
- Neurotrials Research, INC. - Atlanta
Massachusetts
- McLean Hospital - Belmont
- Adams Clinical Trials, LLC - Watertown
Colorado
- Lytle and Weiss, PLLC - Denver
Illinois
- Capstone Clinical Research - Libertyville
Indiana
- Goldpoint Clinical Research, Inc. - Indianapolis
Kansas
- Cypress Medical Research Center, LLC - Wichita
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 319 participants |
| Start Date | 2015-10 |
| Est. Completion | 2016-10 |
| Phase | Phase 2 |
What the finished NCT02564588 record still lists
NCT02564588 is an interventional study that assigns participants to a tested intervention. The registered 319 participants enrollment target is mid-sized for trials with a published cap, below the 1,135-participant average among 37 other Binge-Eating Disorder trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Binge-Eating Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02564588 names 20 study sites across 9 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT02564588 about?
NCT02564588 is a clinical study titled "Dasotraline Binge Eating Disorder Study". Evaluate the efficacy of flexibly-dosed dasotraline compared with placebo in adults with moderate to severe Binge Eating Disorder (BED)
What is the current status of trial NCT02564588?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 319 participants. The study started on 2015-10. Estimated completion is 2016-10.
What conditions does trial NCT02564588 study?
This clinical trial studies the following conditions: Binge-Eating Disorder.
What interventions are being tested in trial NCT02564588?
The interventions under investigation include: Placebo (DRUG), Dasotraline (DRUG).
Who is sponsoring clinical trial NCT02564588?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02564588 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Binge-Eating Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02564588's enrollment target sits among peer trials
319 6th of 37 higher than 32 of 37 other Binge-Eating Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Binge-Eating Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder
RECRUITING · Phase 2
-
A Study of the Effects of Oxytocin in Adults With Binge-eating Disorder
RECRUITING · Phase 2
-
Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy
COMPLETED · Phase 2
-
Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment
COMPLETED · Phase 2
-
Vortioxetine for Binge Eating Disorder
COMPLETED · Phase 2
-
Craving, Binge Eating and Obesity
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05377996 · 319 participants · Phase 1
A Study of XMT-1660 in Participants With Solid Tumors
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia